CORBUS PHARMACEUTICALS HOLDI (CRBP)
US21833P3010 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 4.03M | 3.80M | 6.80M | 1.80M | 900.00K | |||
| Cash Equivalents | 9.69M | 13.20M | 18.30M | 83.60M | 30.90M | |||
| Marketable Securities | 7.18M | 42.20M | 72.60M | N/A | N/A | |||
| Receivables | N/A | N/A | 0.00 | 2.60M | 2.70M | |||
| Other Current Assets | 2.64M | 1.00M | 2.60M | 4.10M | 3.70M | |||
| Total Current Assets | 23.55M | 60.20M | 100.20M | 92.10M | 38.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 4.04M | 5.50M | 7.00M | 9.30M | 10.90M | |||
| Other Non-Current Assets | 690.23K | 600.00K | 500.00K | 900.00K | 100.00K | |||
| Total Non-Current Assets | 4.73M | 6.10M | 7.50M | 10.20M | 10.90M | |||
| TOTAL ASSETS | 28.27M | 66.30M | 107.70M | 102.30M | 49.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 16.21M | 3.10M | 3.90M | 700.00K | 800.00K | |||
| Accrued Expenses | 12.47M | 7.30M | 11.20M | 23.00M | 23.00M | |||
| Accounts Payable | 3.18M | 2.20M | 1.80M | 7.40M | 11.10M | |||
| Other Current Liabilities | 39.45K | 0.00 | 100.00K | 800.00K | 0.00 | |||
| Total Current Liabilities | 31.89M | 12.60M | 17.00M | 31.90M | 34.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 16.00M | 15.60M | 18.00M | 0.00 | |||
| Other Non-Current Liabilities | 3.28M | 4.70M | 6.00M | 7.10M | 8.10M | |||
| Total Non-Current Liabilities | 3.28M | 20.70M | 21.60M | 25.10M | 8.10M | |||
| TOTAL LIABILITIES | 35.18M | 33.30M | 38.60M | 57.00M | 43.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -436.68M | -392.10M | -349.70M | -304.10M | -192.80M | |||
| Additional Paid In Capital | 429.78M | 425.20M | 418.90M | 349.40M | 199.00M | |||
| Common Shares | 440.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -1.56K | -100.00K | -100.00K | N/A | N/A | |||
| Shares Outstanding | 4.42M | 4.20M | 4.20M | 3.30M | 2.20M | |||
| Tangible Book Value per Share | -1.56 | 7.86 | 16.45 | 13.73 | 2.82 | |||
| Total Shareholders' Equity | -6.90M | 33.00M | 69.10M | 45.30M | 6.20M | |||
| TOTAL LIABILITIES AND EQUITY | 28.27M | 66.30M | 107.70M | 102.30M | 49.10M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | 0.48 | 0.23 | 0.40 | N/A | |||
| Current Ratio | 0.74 | 4.78 | 5.89 | 2.89 | 1.09 | |||
| Return On Assets (ROA) | -157.76% | -63.88% | -42.38% | -108.77% | -145.52% | |||
| Return On Equity (ROE) | N/A | -128.33% | -66.05% | -245.63% | -1152.42% | |||
All data in USD